Toxicogenomics Investigation Under the eTOX Project

Publication: Research - peer-reviewJournal article – Annual report year: 2012

Documents

DOI

NullPointerException

View graph of relations

Attrition of drug candidates during pre-clinical development due to toxicity, especially hepatotoxicity and nephrotoxicity, is an important and continuing problem in the pharmaceutical industry. The reasons for this trend may be multifactorial and there is a need to improve toxicity testing paradigms within the industry. Microarray technologies have the ability to generate massive amounts of gene expression information as an initial step to decipher the molecular mechanisms of toxicologic changes, i.e. toxicogenomics. In the context of the eTOX consortium, one of public private partnership within the framework of the European Innovative Medicines Inititative (IMI), we will discuss here how the integration and analysis of toxicogenomics data can help to understanding the mechanism of toxicity
of a compound and so reduce the risk of late-stage failure in pharmaceutical development.
Original languageEnglish
JournalJournal of Pharmacogenomics & Pharmacoproteomics
Publication date2012
Number of pages5
ISSN2153-0645
DOIs
StatePublished
CitationsWeb of Science® Times Cited: No match on DOI

Keywords

  • Toxicogenomics, Gene expression;, Drugs, Rats
Download as:
Download as PDF
Select render style:
APAAuthorCBEHarvardMLAStandardVancouverShortLong
PDF
Download as HTML
Select render style:
APAAuthorCBEHarvardMLAStandardVancouverShortLong
HTML
Download as Word
Select render style:
APAAuthorCBEHarvardMLAStandardVancouverShortLong
Word

Download statistics

No data available

ID: 9785453